Evidence map›Paper›PMID 32038614›Full record

ArticleFrontiers in immunology2019

Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against

Ivana Palucci, Giuseppe Maulucci, Flavio De Maio, Michela Sali, Alessandra Romagnoli, Linda Petrone, Gian Maria Fimia, Maurizio Sanguinetti, Delia Goletti, Marco De Spirito and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Microbiology spectrum · 2026
    Article
  2. Monocyte-Amplified Transcriptional Signatures of Human Diseases.bioRxiv : the preprint server for biology · 2026
    Article
  3. Host-directed therapy for tuberculosis.European journal of medical research · 2025
    Review
  4. Article
  5. High and Low Levels ofInternational journal of molecular sciences · 2023
    Article
  6. Evaluation of Everolimus Activity againstAntibiotics (Basel, Switzerland) · 2023
    Article
  7. Cysteamine/Cystamine Exert Anti-International journal of molecular sciences · 2023
    Article
  8. Review
  9. The Dark Side of the COVID-19 Treatments onMediterranean journal of hematology and infectious diseases · 2022
    Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Ivana PalucciFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Giuseppe MaulucciFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Flavio De MaioFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Michela SaliFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Alessandra RomagnoliElectron Microscopy and Cell Biology Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy.
Linda PetroneTranslational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy.
Gian Maria FimiaElectron Microscopy and Cell Biology Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy.
Maurizio SanguinettiFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Delia GolettiTranslational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy.
Marco De SpiritoFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Mauro PiacentiniElectron Microscopy and Cell Biology Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy.
Giovanni DeloguFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITAgostino Gemelli University Polyclinic · ITUniversità Cattolica del Sacro Cuore · ITIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITSapienza University of Rome · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Host-directed therapies (HDTs) are emerging as a potential valid support in the treatment of drug-resistant tuberculosis (TB). Following our recent report indicating that genetic and pharmacological inhibition of transglutaminase 2 (TG2) restricts

Indexed as

AmikacinAnti-Bacterial AgentsAntitubercular AgentsAutophagyCystamineCysteamineDNA ReplicationDrug SynergismGranulomaGTP-Binding ProteinsHumansMacrophagesMycobacterium tuberculosisProtein Glutamine gamma Glutamyltransferase 2THP-1 CellsTransglutaminasesAmikacinAnti-Bacterial AgentsAntitubercular AgentsCystamineCysteamineGTP-Binding ProteinsProtein Glutamine gamma Glutamyltransferase 2Transglutaminaseshost-directed therapymacrophageMDR-TBMycobacterium tuberculosistransglutaminase 2tuberculosis

Identifiers

PMID32038614
PMCPMC6992558
OpenAlexW3002995437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.